HAE

Haemonetics Corporation (HAE) - 10-K Summary

Business Context and Reporting Period

Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 29, 2003
Business Overview: Haemonetics is a market leader in developing and manufacturing automated systems and single-use disposables for the collection, processing, and surgical salvage of blood. The company operates as a single segment, serving hospitals (surgical blood salvage) and blood collectors (plasma, platelet, and red cell collection). Principal operations are located in the U.S., Europe, and Japan.

Key Financial Metrics (Fiscal Year 2003)

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 5.3% to $337.0 million, driven by volume increases in disposable and software sales. International sales accounted for 62% of total revenue.
• Product Mix: Disposable sales (88.5% of revenue) grew 2.5%. Red Cell disposable sales surged 45.6% due to U.S. blood shortages driving automation adoption. Conversely, Bloodbank disposable sales declined 3.0% due to volume decreases in platelet markets and currency headwinds.
• Profitability: Gross profit remained flat ($0.1 million decrease) despite revenue growth, resulting in a margin compression from 48.4% to 45.9%. This was primarily due to foreign currency losses on plan hedges ($4.5 million loss in 2003 vs. $8.1 million gain in 2002).
• Expenses: Selling, general, and administrative (SG&A) expenses rose 9.9% to $97.7 million, reflecting a full year of expenses from the Fifth Dimension acquisition and increased field support. Research and Development (R&D) remained flat at $19.5 million.
• Capital Allocation: The company repurchased 1.85 million shares of common stock for $50.2 million during the fiscal year.

Guidance, Outlook, and Risks

• Management Commentary: Management highlighted the success of the "CORE" program, which generated $2.9 million in cost savings. The company is redirecting resources from the Chairside Separator to the Red Cell Collector, with clinical trials expected in Europe in fiscal 2004.
• Outlook: The company anticipates OrthoPAT(R) sales will accelerate in fiscal 2004. They expect the Q4 fiscal 2003 effective tax rate of 36.0% to be indicative of fiscal 2004.
• Key Risks:
  • Foreign Exchange: Approximately 62% of sales are international. A strengthening U.S. dollar negatively impacts reported results, though the company uses forward contracts to hedge.
  • Customer Concentration: Sales to the Japanese Red Cross Society represented 23.6% of total accounts receivable and $79.0 million in revenue (23.4% of total revenue).
  • Regulatory: Delays in FDA or international regulatory approvals for new products (e.g., Red Cell Collector) could impact future revenue.
  • Acquisition Contingencies: Potential milestone payments of up to $14.5 million to Baxter for pathogen reduction technology and up to $4.1 million earn-out for Fifth Dimension.

Investor Verification Checklist

• Foreign Currency Impact: Verify the sensitivity of future earnings to U.S. dollar strength, given the 62% international revenue exposure and recent hedge losses.
• Japanese Red Cross Dependency: Assess the risk associated with nearly 24% of revenue coming from a single customer (Japanese Red Cross Society).
• Red Cell Growth Sustainability: Confirm if the 45.6% growth in Red Cell disposables is sustainable or driven by temporary blood shortage conditions.
• Acquisition Milestones: Monitor the status of regulatory approvals for the Baxter pathogen reduction technology to determine timing of the remaining $10.7 million in potential milestone payments.
• Stock Repurchase Program: Note that $26.0 million remains available under the current buyback authorization.